Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT02004522 |
| Title | A Phase 3 Study of IPI-145 Versus Ofatumumab in Patients With Relapsed or Refractory CLL/SLL (DUO) |
| Recruitment | Completed |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | No |
| Sponsors | Infinity Pharmaceuticals, Inc. |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA | NZL | ITA | HUN | GBR | FRA | ESP | DEU | BEL | AUT | AUS |